Lantheus Holdings, Inc. and GE HealthCare announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize piflufolastat F18, known as PYLARIFY in the U.S. market, in Japan. This agreement focuses on prostate cancer diagnostics and companion diagnostic use.
The partnership includes the transfer of regulatory dossiers, manufacturing competencies, and technical support to enable GE HealthCare to drive clinical development in Japan, aiming for potential regulatory submissions and commercial launch. Japan represents a significant market, with the third highest number of prostate cancer cases globally in 2022.
Under the terms of the agreement, Lantheus will receive an upfront license fee, development milestones, and tiered royalties based on product sales in Japan. This collaboration is expected to meaningfully extend the reach of Lantheus's diagnostic imaging agent in key international markets, addressing a critical clinical need and laying the foundation for a more personalized approach to prostate cancer detection and monitoring.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.